[HTML][HTML] Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis
U Schmid, C Doege, C Dallinger, M Freiwald - Pulmonary Pharmacology & …, 2018 - Elsevier
Background Nintedanib is a potent intracellular inhibitor of tyrosine kinases, including the
receptor kinases vascular endothelial growth factor, platelet-derived growth factor and …
receptor kinases vascular endothelial growth factor, platelet-derived growth factor and …
Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis
U Schmid, C Doege, C Dallinger… - Pulmonary …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Nintedanib is a potent intracellular inhibitor of tyrosine kinases, including the
receptor kinases vascular endothelial growth factor, platelet-derived growth factor and …
receptor kinases vascular endothelial growth factor, platelet-derived growth factor and …
Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis.
U Schmid, C Doege, C Dallinger… - Pulmonary …, 2017 - europepmc.org
Background Nintedanib is a potent intracellular inhibitor of tyrosine kinases, including the
receptor kinases vascular endothelial growth factor, platelet-derived growth factor and …
receptor kinases vascular endothelial growth factor, platelet-derived growth factor and …